Propofol formulations with non-reactive container closures
First Claim
Patent Images
1. A sterile pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol, and less than about 10% by weight solvent for propofol, wherein said composition is stored in a container having a closure wherein said closure is inert to propofol.
14 Assignments
0 Petitions
Accused Products
Abstract
A sterile pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol, optionally albumin, and less than about 10% by weight solvent for propofol, wherein said composition is stored in a container having a closure wherein said closure is inert to propofol.
-
Citations
64 Claims
- 1. A sterile pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol, and less than about 10% by weight solvent for propofol, wherein said composition is stored in a container having a closure wherein said closure is inert to propofol.
- 29. A sterile pharmaceutical composition in the form of an oil-in-water emulsion for parenteral administration of propofol, said composition comprising an oil phase comprising propofol, and less than about 10% by weight solvent for propofol and an aqueous phase comprising water for injection and wherein the composition includes a stabilizing layer for the oil phase, said stabilizing layer comprising a surfactant and a protein, wherein said composition is stored in a container having a closure wherein said closure is inert to propofol.
-
46. The sterile pharmaceutical composition of claim 46, wherein the material is selected from the group consisting of bromobutyl rubber, chlorobutyl rubber, a fluoropolymer, silicone, and mixtures thereof.
-
52. A sterile, injectable pharmaceutical composition comprising:
-
a) microdroplets having a mean size of from about 20 nanometers to about 1000 nanometers, said microdroplets comprising a sphere of propofol surrounded by a stabilizing layer comprising a phospholipid and devoid of oils capable of supporting bacterial growth; and
b) a pharmaceutically acceptable injectable carrier, wherein said composition is stored in a container having a closure, wherein said closure is inert to propofol. - View Dependent Claims (53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)
-
Specification